NLRP3 and colitis: Oral administration of MCC950, the best characterized direct and selective NLRP3 inhibitor, with a half-maximal inhibitory concentration (IC50) within the nanomolar range, Oridonin, which competes for binding to NEK7, or INF39, an irreversible inhibitor of the ATPase domain of NLRP3, have shown efficacy against colitis in animal models [85–88].